Table 1 Characteristics of the 300 patients with chronic myeloproliferative disorders

Disease
JAK-V617F

subtype
mutation

PV
ET
IMF
Positive
Negative
P-value1"
Patients
33
49
6
59
29

sex (male/female)
70/40
27/22
5/1
35/24
19/10
0.358
Age
68 13
67 14
72 16 70 12
66 17
0.312
Disease duration, median 55 (14124(7035(10-180)
56(12-273)
29(10-264)
0.005
(range}
273}
264)
WBC (x109/L)
Hb {g/dl}
Platelet (x109/L)
Erythropoietin
BM fibrosis (+),%
Splenomegaly, %
CAD or HT (+), %
JAK2-V617F(+), n/N{%)
Thrombosis/haemorrhage
*

12.1 6.1

8.9 4.8

8.9 7.1 11.2 5.8

8.6 5.5

0.002

14.2 2.1 12.6 2.2

9.0 1.8 13.2 2.5

12.2 2.6

0.036

475 255

514 353

0.728

7.7 3.3 15.5 11.6 18.4 12 12.0 9.7

9.7 3.9

0.71

442
338

38
55
55
28/33
(85)
40915

583 227

56 32

40
53
43

100
100
33

50
72
49

333
39
41

0.358
0.019
0.646

29/49 (59)

2/6 (33)

100%

0%

40921

0/1

40926

40942

0.22

4/21/12

Table . Proportion (%. 95% confidence interval) of younger

subjects among patients with advanced CRC (2006-2007).
Age
Total
Females
Males
(years)

T3/T4 stage
18.5

25.0

13.3

<55

(11.727.1)

(13.6-39.6)

(5.9-24.6)

<60

32.4
(23.742.1)

35.4

30.0

(22.2-50.5)

(18.8-43.2)

N1/N2

<55

<60

25.0

34.6

16.7

(14.4-38.4)

(17.2-55.7)

(5.6-34.7)

35.7

42.3

30.0

(23.4-49.6)

(23.4-63.1)

(14.7-49.4)

Poor Differentiation
29.0

33.3

23.1

4/21/12

Table : Number of Lymph Nodes Examined in Relationship to Different Clinical

and Histopathologic Variables

Number of lymph nodes

Sex

P Value

Male

Female

11.34

0.168

1270

Tumor Location

Proximal to splenic flexure

Distal to splenic flexure

12.59

0.6S4

12.34

Urgency of operation

Elective

Emergency

12.08

0.379

12.84

Depth of tumor invasion

T3

T4

1236

0.136

10.93

4/21/12

Table : 5-year Disease Free Survival Rates in Relationship to

Different Clinical and Histopathologic Variables
5-year
Disease
P
Free
Survival

Sex

Male

60%

0.103

Female

66%

Tumor Location

Proximal to splenic flexure

64%

0.364

Distal to splenic flexure

62%

Urgency of operation

Elective

65%

0.002

Emergency

50%

Depth of tumor invasion

T3

65%

0.000

4/21/12